Hims & Hers Health, Inc.
Every calculator, already run for HIMS
Open the full toolkit →You have the numbers on HIMS. Get the argument.
A written report on which of these readings actually decide the outcome for Hims & Hers Health, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
15 analysts covering HIMSAnalyst Price Target Disagreement for Hims & Hers Health, Inc.
Wall Street's bull case implies +45% from the current price; the bear case implies -21%. A 66% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for HIMS
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Hims & Hers Health, Inc.
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair ca…
See a finished HIMS report first
We've already published a full institutional-style research report on Hims & Hers Health, Inc.. Read it end to end before you generate your own.
HIMS — frequently asked
Is HIMS a buy right now?
Wall Street's consensus rating on Hims & Hers Health, Inc. is Hold across 15 analysts, with a mean price target of $31.15 (+7% vs. the current $29.00). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is HIMS overvalued?
HIMS trades at — trailing earnings, against a DCF fair value of $42 per share. The current price implies 0% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is HIMS's next earnings date?
Hims & Hers Health, Inc. is next scheduled to report earnings around Nov 9, 2026. A full HIMS research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Hims & Hers Health, Inc.?
Analysts covering Hims & Hers Health, Inc. (HIMS) range from a bear-case target of $23.00 to a bull-case high of $42.00, with a mean consensus target of $31.15 across 13 analysts. The spread of $19.00 (66% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Hims & Hers Health, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Hims & Hers Health, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full HIMS research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Hims & Hers Health, Inc., in minutes. 3 free reports included with every account — no credit card required.